COMMUNIQUÉS West-GlobeNewswire

Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes
12/01/2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. DUBLIN, Jan. 12, [...]
Nyxoah Annonce ses Résultats Préliminaires pour le Quatrième Trimestre et l'Ensemble de l'Exercice 2025 et Communique des Prévisions de Chiffre d'Affaires pour le Premier Trimestre 2026
12/01/2026
INFORMATIONS PRIVILÉGIÉES INFORMATIONS RÉGLEMENTÉES Nyxoah Annonce ses Résultats Préliminaires pour le Quatrième Trimestre et l'Ensemble de l'Exercice 2025 et Communique des Prévisions de Chiffre d'Affaires pour le [...]
Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026
12/01/2026
INSIDE INFORMATION REGULATED INFORMATION Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026 Strong Start in First Full Quarter of U [...]
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
12/01/2026
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced that it has granted to Ellen Rose, the new Senior Vice President, Corporate [...]
SafeSpace Global Corporation (OTCID: SSGC) Issues CEO Letter to Shareholders
12/01/2026
Knoxville, TN, Jan. 12, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID: SSGC), a leading AI technology company delivering multimodal safety solutions across education, healthcare, transportation, and [...]
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
12/01/2026
- Preliminary unaudited Q4 and Full Year 2025 net Attruby ® product revenue of $146.0 million and $362.4 million, respectively - Attruby (acoramidis) is rapidly becoming the first-choice therapy for newly diagnosed ATTR [...]
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
12/01/2026
Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-treated nusinersen patients with SMA 1 Biogen is dedicated to [...]
Oncovita announces a strategic partnership with Infinitusbio.AI to explore the design and optimize the development of new therapeutic candidates from its Measovir® platform.
12/01/2026
Oncovita announces a strategic partnership with Infinitusbio.AI to explore the design and optimize the development of new therapeutic candidates from its Measovir® platform. San Diego, United-States and Paris, France – [...]
SAFE GROUP NOMME CYRIL GONCALVES AU POSTE DE DIRECTEUR ADMINISTRATIF ET FINANCIER
12/01/2026
SAFE GROUP NOMME CYRIL GONCALVES AU POSTE DE DIRECTEUR ADMINISTRATIF ET FINANCIER Renforcement de l’équipe de direction Fleurieux-sur-l’Arbresle – France – 12 janvier 2026 – 18h - Safe (FR001400ZU25 – ALSAF), annonce [...]
IBA SA – NOTIFICATION TRANSPARENCE
12/01/2026
(article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 12 janvier 2026, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), le [...]
IBA – TRANSPARENCY NOTIFICATION
12/01/2026
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, January 12, 2026 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world’s leading [...]
Nudj Health Names Dr. David Nash
12/01/2026
Global leader of Population Health and Public Accountability for Health Outcomes Joins Advisory Board SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- JP Morgan Healthcare Conference -- Nudj Health, the leading AI- [...]
Sorevna Announces Strategic Expansion into Bath and Body Sector
12/01/2026
New York, USA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Sorevna , a company in the cosmetics industry, today announced its planned entry into the bath and body care segment, expanding its existing product portfolio. The [...]
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
12/01/2026
NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet [...]
Microbot Medical Continues its 2025 Momentum; Announces Key 2026 Milestones
12/01/2026
Limited Market Release (LMR) of the LIBERTY ® System is on Schedule Building on Positive Customer Feedback and Growing Market Enthusiasm, the Company Prepares for Full Market Release (FMR) in Q2 HINGHAM, Mass., Jan. 12 [...]
Outset Medical Reports Unaudited Fourth Quarter and 2025 Results
12/01/2026
Appoints Medical Technology Veteran Karen N. Prange to Board of Directors SAN JOSE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind [...]
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook
12/01/2026
New name reflects the Company’s strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature gene-editing capabilities Pre-IND meeting held in 4Q 2025 following MGX-001 [...]
Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting
12/01/2026
The FDA has granted an in-person Type C meeting during the first quarter of 2026 New independent analyses across large observational ALS cohorts demonstrate that modest (~10%) NfL reductions are significantly associated [...]
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
12/01/2026
Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR [...]

Pages